Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT04667637
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Hui-Sheng Chen
- Registry
-
NCT04667637
-
- Other papers using this trial's data
- Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04667637. Randomized; double masking; primary purpose treatment. Start 2021-02-23 (actual); primary completion 2022-10-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol
- Condition
- Stroke
- Condition
- Endovascular Thrombectomy
- Intervention (Drug)
- edaravone dexborneol
- Lead sponsor
- Hui-Sheng Chen
Record details
- Record id
cardio:ct-nct04667637- Content hash
49e2580626dd72f23772654160fa97f8ab8574548b78190166cf6ecd93f7940a